Your session is about to expire
← Back to Search
Pembrolizumab + V940 for Bladder Cancer
Study Summary
This trial aims to test if a drug called V940, when given with pembrolizumab, is safer and more effective than pembrolizumab alone in treating individuals with a specific type
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this medical study actively seeking participants at the moment?
"According to the details found on clinicaltrials.gov, this investigation is presently enrolling participants. The trial's initial posting date was 28th March 2024 and its most recent update was on 5th April 2024."
How many individuals are currently enrolled in this medical research study?
"Indeed, the information available on clinicaltrials.gov highlights that this investigation is presently seeking suitable candidates. The trial was initially disclosed on March 28th, 2024 and underwent its most recent revision on April 5th, 2024. A total of 200 individuals are being sought to participate in this study across two designated sites."
Has the combination of Pembrolizumab and V940 received official approval from the FDA?
"According to our evaluation at Power, the safety rating for Pembrolizumab + V940 is 2 on a scale of 1 to 3. This assessment aligns with being in Phase 2 where there exists some data indicating safety but not efficacy yet."
Share this study with friends
Copy Link
Messenger